# Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia

> **NCT00895297** · PHASE2 · TERMINATED · sponsor: **European Society for Blood and Marrow Transplantation** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib (Sprycel)

## Key facts

- **NCT ID:** NCT00895297
- **Lead sponsor:** European Society for Blood and Marrow Transplantation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-11
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** Slow recruitment. No safety concerns during this study.
- **Last updated:** 2011-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895297, "Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00895297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*